These Company's Have 74-Day Letter As A Milestone Event Triggering A Partnership Payment
In Mannkind's case it could be the trigger that gets a deal signed and announced.
"Topotarget's partner Spectrum Pharmaceuticals has filed belinostat with the FDA. The next landmark is the 74-day letter, which should be received on or before 22 February 2014, with potential approval in H214. If the application is accepted by the FDA, Topotarget will receive a $10m milestone payment and 1m Spectrum shares from its partner, and a further $25m in cash on approval. We remain optimistic that belinostat will be approved, based on the BELIEF study data compared to other comparable studies with approved products."